Improved therapeutic efficacy of mammalian expressed-recombinant interferon gamma against ovarian cancer cells

Experimental Cell Research

Volumn 359, Issue 1, 2017, Pages 20-29

  Razaghi, Ali ^a   Villacrés, Carina ^b   Jung, Vincent ^b   Mashkour, Narges ^a   Butler, Michael ^b   Owens, Leigh ^a   Heimann, Kirsten ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

FADD; Glycosylation; Interferon gamma; Ovarian cancer; SKOV3; Therapeutic efficacy

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE 2; FAS ASSOCIATED DEATH DOMAIN PROTEIN; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROCASPASE 3; RECOMBINANT GAMMA INTERFERON; GAMMA INTERFERON; IFNG PROTEIN, HUMAN; POLYSACCHARIDE; RECOMBINANT PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DEGLYCOSYLATION; ENZYME ACTIVATION; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; FUCOSYLATION; GENE EXPRESSION SYSTEM; HEK293 CELL LINE; HOC-7 CELL LINE; HUMAN; HUMAN CELL; HYDROPHILIC INTERACTION CHROMATOGRAPHY; MTT ASSAY; OAW42 CELL LINE; OVARY CANCER; OVCAR-3 CELL LINE; OVCAR-4 CELL LINE; OVCAR-5 CELL LINE; PA-1 CELL LINE; PEO1 CELL LINE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; SIALYLATION; SK-OV-3 CELL LINE; WESTERN BLOTTING; GLYCOSYLATION; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; GLYCOSYLATION; HEK293 CELLS; HUMANS; INTERFERON-GAMMA; OVARIAN NEOPLASMS; POLYSACCHARIDES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 85028309456     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2017.08.014     Document Type: Article

References (47)

1. Young, Ha, Hardy, K.J., Role of interferon-y in immune cell regulation. J. Leukoc. Biol. 58 (1995), 373–381.
2. Razaghi, A., Owens, L., Heimann, K., Review of the recombinant human interferon gamma as an immunotherapeutic: impacts of production platforms and glycosylation. J. Biotechnol. 240 (2016), 48–60.
3. Sareneva, T., Cantell, K., Pyhala, L., Pirhonen, J., Julkunen, I., Effect of carbohydrates on the pharmacokinetics of human interferon-gamma. J. Interferon Res. 13 (1993), 267–269.
4. Sareneva, T., Pirhonen, J., Cantell, K., Julkunen, I., N-glycosylation of human interferon-y: glycans at Asn-25 are critical for protease resistance. Biochem. J. 308 (1995), 9–14.
5. Miyakawa, N., Nishikawa, M., Takahashi, Y., Ando, M., Misaka, M., Watanabe, Y., Takakura, Y., Prolonged circulation half-life of interferon gamma activity by gene delivery of interferon gamma-serum albumin fusion protein in mice. J. Pharm. Sci. 100 (2011), 2350–2357.
6. Razaghi, A., Tan, E., Lua, L.H., Owens, L., Karthikeyan, O.P., Heimann, K., Is Pichia pastoris a realistic platform for industrial production of recombinant human interferon gamma?. Biologicals 45 (2017), 52–60.
7. Razaghi, A., Huerlimann, R., Owens, L., Heimann, K., Increased expression and secretion of recombinant hIFNγ through amino acid starvation-induced selective pressure on the adjacent HIS4 gene in Pichia pastoris. Eur. Pharm. J. 62 (2015), 43–50.
8. Ghaderi, D., Zhang, M., Hurtado-Ziola, N., Varki, A., Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol. Genet. Eng. Rev. 28 (2012), 147–176.
9. Sola, R.J., Griebenow, K., Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs 24 (2010), 9–21.
10. Dunn, G.P., Koebel, C.M., Schreiber, R.D., Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6 (2006), 836–848.
11. Windbichler, G.H., Hausmaninger, H., Stummvoll, W., Graf, A.H., Kainz, C., Lahodny, J., Denison, U., Muller-Holzner, E., Marth, C., Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br. J. Cancer 82 (2000), 1138–1144.
12. Alberts, D.S., Marth, C., Alvarez, R.D., Johnson, G., Bidzinski, M., Kardatzke, D.R., Bradford, W.Z., Loutit, J., Kirn, D.H., Clouser, M.C., Markman, M., Consortium, G.C.T., Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol. Oncol. 109 (2008), 174–181.
13. Barton, C., Davies, D., Balkwill, F., Burke, F., Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur. J. Cancer 41 (2005), 1474–1486.
14. Wall, L., Burke, F., Barton, C., Smyth, J., Balkwill, F., IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin. Cancer Res. 9 (2003), 2487–2496.
15. Burke, F., Smith, P.D., Crompton, M.R., Upton, C., Balkwill, F.R., Cytotoxic response of ovarian cancer cell lines to IFN-gamma is associated with sustained induction of IRF-1 and p21 mRNA. Br. J. Cancer 80 (1999), 1236–1244.
16. Tourneur, L., Chiocchia, G., FADD: a regulator of life and death. Trends Immunol. 31 (2010), 260–269.
17. Schinske, K.A., Nyati, S., Khan, A.P., Williams, T.M., Johnson, T.D., Ross, B.D., Tomas, R.P., Rehemtulla, A., A novel kinase inhibitor of FADD phosphorylation chemosensitizes through the inhibition of NF-kappaB. Mol. Cancer Ther. 10 (2011), 1807–1817.
18. Patel, S., Murphy, D., Haralambieva, E., Abdulla, Z.A., Wong, K.K., Chen, H., Gould, E., Roncador, G., Hatton, C., Anderson, A.P., Banham, A.H., Pulford, K., Increased expression of phosphorylated FADD in anaplastic large cell and other T-Cell lymphomas. Biomark. Insights 9 (2014), 77–84.
19. Boselli, D., Losana, G., Bernabei, P., Bosisio, D., Drysdale, P., Kiessling, R., Gaston, J.S., Lammas, D., Casanova, J.L., Kumararatne, D.S., Novelli, F., IFN-gamma regulates Fas ligand expression in human CD4+ T lymphocytes and controls their anti-mycobacterial cytotoxic functions. Eur. J. Immunol. 37 (2007), 2196–2204.
20. Royle, L., Radcliffe, C.M., Dwek, R.A., Rudd, P.M., Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. Methods Mol. Biol. 347 (2006), 125–143.
21. Hu, X., Zhang, Z., Understanding the genetic mechanisms of cancer drug resistance using genomic approaches. Trends Genet. 32 (2016), 127–137.
22. Putt, K.S., Chen, G.W., Pearson, J.M., Sandhorst, J.S., Hoagland, M.S., Kwon, J.T., Hwang, S.K., Jin, H., Churchwell, M.I., Cho, M.H., Doerge, D.R., Helferich, W.G., Hergenrother, P.J., Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat. Chem. Biol. 2 (2006), 543–550.
23. Saeki, K., Yuo, A., Kato, M., Miyazono, K., Yazaki, Y., Takaku, F., Cell density-dependent apoptosis in HL-60 cells, which is mediated by an unknown soluble factor, is inhibited by transforming growth factor 1 and overexpression of Bcl-2. J. Biol. Chem. 272 (1997), 20003–20010.
24. Pronsato, L., La Colla, A., Ronda, A.C., Milanesi, L., Boland, R., Vasconsuelo, A., High passage numbers induce resistance to apoptosis in C2C12 muscle cells. Biocell: Off. J. Soc. Latinoam. De. Microsc. Electron. … et al. 37 (2013), 1–9.
25. Pasparakis, M., Vandenabeele, P., Necroptosis and its role in inflammation. Nature 517 (2015), 311–320.
26. Li, P., Du, Q., Cao, Z., Guo, Z., Evankovich, J., Yan, W., Chang, Y., Shao, L., Stolz, D.B., Tsung, A., Geller, D.A., Interferon-gamma induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1). Cancer Lett. 314 (2012), 213–222.
27. Liu, Q., Liu, X., Gao, J., Shi, X., Hu, X., Wang, S., Luo, Y., Overexpression of DOC-1R inhibits cell cycle G1/S transition by repressing CDK2 expression and activation. Int. J. Biol. Sci. 9 (2013), 541–549.
28. Frokjaer, S., Otzen, D.E., Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 4 (2005), 298–306.
29. Bell, B.D., Leverrier, S., Weist, B.M., Newton, R.H., Arechiga, A.F., Luhrs, K.A., Morrissette, N.S., Walsh, C.M., FADD and caspase-8 control the outcome of autophagic signaling in proliferating T cells. Proc. Natl. Acad. Sci. 105 (2008), 16677–16682.
30. Thapa, R.J., Basagoudanavar, S.H., Nogusa, S., Irrinki, K., Mallilankaraman, K., Slifker, M.J., Beg, A.A., Madesh, M., Balachandran, S., NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis. Mol. Cell Biol. 31 (2011), 2934–2946.
31. Vivo, C., Levy, F., Pilatte, Y., Fleury-Feith, J., Chretien, P., Monnet, I., Kheuang, L., Jaurand, M.C., Control of cell cycle progression in human mesothelioma cells treated with gamma interferon. Oncogene 20 (2001), 1085–1093.
32. Kano, A., Watanabe, Y., Takeda, N., Aizawa, T.S.-i., Analysis of IFN-γ-induced cell cycle arrest and cell death in hepatocytes. J. Biochem. 121 (1997), 677–683.
33. Huang, X., Barchi, J.J. Jr., Lung, F.D., Roller, P.P., Nara, P.L., Muschik, J., Garrity, R.R., Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135. Biochemistry 36 (1997), 10846–10856.
34. Xu, X., Fu, X.Y., Plate, J., Chong, A.S., IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 58 (1998), 2832–2837.
35. Rosner, D., Stoneman, V., Littlewood, T., McCarthy, N., Figg, N., Wang, Y., Tellides, G., Bennett, M., Interferon-gamma induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K- and Akt-dependent mechanism. Am. J. Pathol. 168 (2006), 2054–2063.
36. Jean, M.D.S., Brignole, Fi, Feldmann, G., Goguel, A., Baudouin, C., Interferon-γ induces apoptosis and expression of inflammation-related proteins in Chang conjunctival cells. Invest Ophthalmol. Vis. Sci. 40 (1999), 2199–2212.
37. Pm, C., Ap, I., Pm, H., The macroheterogeneity of recombinant human interferon‐gamma produced by Chinese‐hamster ovary cells is affected by the protein and lipid content of the culture medium. Biotechnol. Appl. Biochem. 21 (1995), 87–100.
38. Jenkins, N., Castro, P., Menon, S., Ison, A., Bull, A., Effect of lipid supplements on the production and glycosylation of recombinant interferon-gamma expressed in CHO cells. Cytotechnology 15 (1994), 209–215.
39. James, D.C., Freedman, R.B., Hoare, M., Ogonah, O.W., Rooney, B.C., Larionov, O.A., Dobrovolsky, V.N., Lagutin, O.V., Jenkins, N., N-glycosylation of recombinant human interferon-y produced in different animal expression systems. Biotechnology, 13, 1995, 64771.
40. Rieder, J., Jahnke, R., Schloesser, M., Seibel, M., Czechowski, M., Marth, C., Hoffmann, G., Nitric oxide-dependent apoptosis in ovarian carcinoma cell lines. Gynecol. Oncol. 82 (2001), 172–176.
41. Kim, E.J., Lee, J.M., Namkoong, S.E., Um, S.J., Park, J.S., Interferon regulatory factor-1 mediates interferon-gamma-induced apoptosis in ovarian carcinoma cells. J. Cell Biochem. 85 (2002), 369–380.
42. Guan, Y.-Q., Zheng, Z., Liang, L., Li, Z., Zhang, L., Du, J., Liu, J.-M., The apoptosis of OVCAR-3 induced by TNF-α plus IFN-γ co-immobilized polylactic acid copolymers. J. Mater. Chem., 22, 2012, 14746.
43. Alappat, E.C., Feig, C., Boyerinas, B., Volkland, J., Samuels, M., Murmann, A.E., Thorburn, A., Kidd, V.J., Slaughter, C.A., Osborn, S.L., Winoto, A., Tang, W.J., Peter, M.E., Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol. Cell 19 (2005), 321–332.
44. Lee, E.W., Seo, J., Jeong, M., Lee, S., Song, J., The roles of FADD in extrinsic apoptosis and necroptosis. BMB Rep. 45 (2012), 496–508.
45. Li, L.C., Jayaram, S., Ganesh, L., Qian, L., Rotmensch, J., Maker, A.V., Prabhakar, B.S., Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells. Am. J. Obstet. Gynecol. 205:362 (2011), e312–e325.
46. Pyo, J.O., Jang, M.H., Kwon, Y.K., Lee, H.J., Jun, J.I., Woo, H.N., Cho, D.H., Choi, B., Lee, H., Kim, J.H., Mizushima, N., Oshumi, Y., Jung, Y.K., Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. J. Biol. Chem. 280 (2005), 20722–20729.
47. Park, S.Y., Seol, J.W., Lee, Y.J., Cho, J.H., Kang, H.S., Kim, I.S., Park, S.H., Kim, T.H., Yim, J.H., Kim, M., Billiar, T.R., Seol, D.W., IFN-gamma enhances TRAIL-induced apoptosis through IRF-1. Eur. J. Biochem. 271 (2004), 4222–4228.